PRMT5 and adrenal cortex carcinoma: While an early signal of treatment response to PRT543 without evidence of toxicities has been observed in a subset of patients with ACC [40, 44, 45], preclinical studies investigating the effect of PRMT5 blockade remain inadequate, in part due to the limited availability of the experimental models for this rare malignancy.